The BD Physioject disposable auto-injector from BD Medical, a division of Becton, Dickinson and Company (BD), is for self-injection of drugs for chronic diseases such as rheumatoid arthritis, multiple sclerosis, asthma and osteoporosis.
The auto-injector offers easy, one-button activation, 360° view of the drug and injection process, visual confirmation of the end of injection, and protection of the needle after injection.
BD Physioject can be customised to offer a modified external design, flexible injection duration, a range of possible subcutaneous injection depths, and various syringe options (such as an end-of-dose indicator). It also includes a straightforward two-part assembly process that simplifies production and manufacturing.
The device is used in combination with the BD Hypak for Biotech syringe, a primary container for biologics, to provide a low level of interaction with such drugs.
Merck Serono uses Physioject as the platform for RebiDose, the Rebif pre-filled pen, for the treatment of multiple sclerosis. RebiDose was approved in Europe and Australia in October 2010.
BD Physioject allows self-injection of drugs for chronic diseases
Disposable device offers one-button activation and needle protection after injection
You may also like
Trending Articles
Upcoming event
You may also like
Drug Delivery
Aptar Pharma announces development and license agreement with BD to bring a novel autoinjector to market
AptarGroup is a leading global supplier of a broad range of innovative dispensing solutions for the beauty, personal care, home care, prescription drug, consumer healthcare, injectables, food and beverage markets